Just as no two people are the same, no two runners have the same stride length, either. The rate, rhythm, and distance from the body at which we strike our feet against the ground is different for ...
Just as no two people are the same, no two runners have the same stride length, either. The rate, rhythm, and distance from ...
CHICAGO, IL—The pool of patients who could potentially benefit from a glucagon-like peptide 1 (GLP-1) receptor agonist has expanded, thanks to new data showing that people with diabetes and ...
STRIDE investigator Marc Bonaca, MD, MPH, University of Colorado School of Medicine, highlights how the data could provide insight into peripheral artery disease and type 2 diabetes treatment options.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results